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Abstract 
The continued use of antibiotics will undoubtedly lead to increases in antibiotic resistant 
bacteria and decreased effectiveness of antibiotic therapeutics. Therefore, a need exists for new 
therapeutic agents which effectively treat bacterial outbreaks but limit the ability of microbes to 
become resistant over time. 
Antimicrobial peptides are innate defense peptides produced by multicellular organisms to 
combat a wide variety of pathogens present in the environment. They are naturally produced by the 
host, exhibit remarkably diverse structures and bioactivity both in and amongst species, and function 
through a variety of bactericidal mechanisms which limit bacterial resistance. These characteristics 
make them a potential source for the development of new anti-infective agents. The purpose of this 
thesis was to assess the antimicrobial activity and stimulatory potential of natural and synthetically 
derived peptides for use in Atlantic salmon (Salmo salar). 
In this research, four peptides (P9-4, P11-5, P11-6, and Protegrin-1) were shown to be 
effective at inhibiting salmon pathogens Yersinia ruckeri and Aeromonas hydrophila, with minimum 
inhibitory concentrations (MIC) of less than 20 µM in saline conditions. Additionally, all peptides 
were effective against Escherichia coli (MIC between 2.5 µM-40 µM). The antimicrobial activity and 
haemolytic ability of these peptides was greatly reduced in the presence of serum, with limited 
haemolysis observed in erythrocytes incubated with 640 µM of each peptide. Furthermore, P9-4 and 
P11-5 were shown to significantly increase transcription of the chemokine interleukin-8 (IL-8) in 
serum cultures of Atlantic salmon peripheral blood leukocytes (PBL) following six hour in vitro 
stimulation. Results from these experiments suggest that the potent antimicrobial and conversely 
haemolytic ability, of peptides commonly seen in conventional media becomes more modest when 
subjected to more realistic biologically relevant conditions. Additionally, two peptides were capable 
of influencing expression of the chemokine IL-8 which plays a role in chemotaxis of immune cells. 
This provides preliminary evidence for the use of these peptides as immunostimulants. 
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The ability of antimicrobial peptides to modulate the functions of immune cells in Atlantic 
salmon was explored.  Functional assays were used to assess the direct stimulatory capacity of 
antimicrobial peptides on the induction of phagocytosis, cell proliferation, and respiratory burst 
which play an important role in the immune system of teleost fish. Synthetic antimicrobial peptides 
were selected as well as the two known Atlantic salmon cathelicidins (asCATH1 and asCATH2) and 
examined in these experiments. The synthetic peptides K6L2W3 and HHC-10 were shown to 
significantly improve phagocytic ability, phagocytic index, and respiratory burst in head kidney 
leukocytes (HKLs). Additionally, HHC-10 was shown to significantly improve cell proliferation. Of the 
natural antimicrobial peptides, asCATH2 significantly improved phagocytosis, cell proliferation and 
respiratory burst whereas asCATH1 did not. Previous work involving these cathelicidins suggested 
that functional difference exists between these peptides and that asCATH2 may play a multifaceted 
biological role during infections. This work provides supplemental evidence to support that claim. 
The findings in this thesis show that some antimicrobial peptides possess potent 
antimicrobial abilities while others act to modulate cells to improve pathogen destruction and 
infection clearance. This is in agreement with previous research indicating that peptides exhibit a 
structure-activity relationship and diverse mechanisms of action. Moreover, this research further 
supports the potential of antimicrobial peptides as a natural blueprint for new drug development 
with applications in aquaculture and showcases the versatility of these peptides in teleost fish. 
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The aquatic environment is inhabited by a wide variety of pathogenic microorganisms 
which interact with fish.  To combat this, teleost fish have had to evolve an immune system 
capable of detecting a wide variety of microbes, protecting against disease, and assisting in 
the maintenance of homeostasis. The immune system of teleost fish has traditionally been 
divided into the innate and the adaptive immune system (Figure 1). While many stand-alone 
functions exist within each system, there is a growing body of evidence that suggests 
interplay between the two. In general, the innate response is activated before the adaptive 
response and helps to determine the nature of subsequent responses [1]. The innate 
immune system is comprised of physical barriers, cellular components, and humoral 
responses [1, 2]. These function in the trafficking of immune cells to sites of infection, 
recognition, destruction, and clearance of pathogens or dead cells in an immediate manner 
[3]. This system, which is evolutionarily conserved amongst multicellular organisms, is non-
specific and a relatively temperature independent response in poikilotherms [2]. The 
adaptive response works in conjunction with the innate response and also is composed of 
humoral and cellular components. This response is highly specific and aids in improved 
recognition of the pathogen and is a more finely-tuned immunological response but is 
biologically costly, time-consuming, and temperature dependant [4]. Furthermore, adaptive 
immunity is closely associated with immunological memory and the production of 
antibodies to combat systemic, prolonged infections.  
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 Figure 1. Summary of immunity in teleost fish.
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1.1 Lymphoid system in fish 
The lymphoid system in fish contains a variety of tissues and organs which play an important 
role in both the adaptive and innate immune response of teleost. Fish lymphoid organs and tissues 
include the thymus, interbranchial lymphoid tissue (ILT), kidney, liver, gut-associated lymphoid tissue 
(GALT), spleen, and skin-associated lymphoid tissue (SALT) (Figure 2).  
 
Figure 2. Salmonid fish highlighting the distribution of lymphoid organs and tissue based on 
images composited from Animal Life (http://animalia-life.com/). 
The focus of this thesis is the non-specific immune response, primarily the interplay between 
cell-mediated immunity and humoral immunity. Therefore, these tissues are important because they 
are immunological sites and physical conduits for a variety of cells associated with innate immunity 
including monocytes, macrophages, neutrophils and granulocytes [5]. 
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1.2 Components of the innate immune system in fish 
The innate immune system represents the first and primary line of defence against pathogens in 
fish. It is an evolutionarily conserved and fundamentally important defense mechanism in fish. It can 
be split up into physical  and chemical barriers (epithelial and mucosal), cellular components, and 
humoral responses [5]. The epithelial surfaces and mucosal barrier of the skin, gills, and alimentary 
tract act as physical barriers against pathogen invasion in fish [6]. While the epidermis and gill 
epithelium act primarily as an interface to the external environment, they also provide a substrate 
for antimicrobial activity. Mucus prevents pathogen adherence due to its continuous production and 
subsequent sloughing  [7]. Additionally, mucus serves as a chemical storehouse for a wide variety of 
important innate immune components including lysozyme, lectins, immunoglobulins, proteases, and 
antibacterial peptides [7-9]. These secretory components are involved in direct pathogen 
destruction through a diverse range of antibacterial mechanisms, opsonisation of particles, 
complement activation, and the elicitation of a pro- or anti-inflammatory response [2, 10, 11]. 
The innate immune system relies heavily on pattern recognition receptors (PRRs) to 
distinguish between self and non-self and recognize pathogens [12-14]. These proteins are 
expressed by cells of the immune system and function through recognition of pathogen associated 
molecular patterns (PAMPs) and damage associated molecular patterns (DAMPs). Common bacterial 
PAMPs include lipopolysaccharide (LPS), mannose, bacterial DNA/RNA, flagellin, peptidoglycans, and 
lipoteichoic acids [3].  The four main PRRs which have been described in fish include Toll-like 
receptors (TLRs), NOD-like receptors (NLR), C-type lectin receptors (CLRs) and peptidoglycan 
recognition proteins (PGRPs) which can be classified according to their function or association with a 
particular ligand  [12, 15]. Of these, TLRs are considered to be the best understood and 17 types 
have been recognized in fish [15]. Upon activation of TLRs, an innate humoral response is elicited. 
Molecules associated with this response include proinflammatory cytokines and type I interferons 
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(IFNs) which are important in modulating innate and adaptive immunity, as well as direct 
antimicrobial compounds such as antimicrobial peptides [12, 14]. 
1.3  Antimicrobial peptides (AMPs) 
Antimicrobial peptides (AMPs) are amphipathic peptides which play an important role in 
innate defense [16-18]. They have been isolated from a wide variety of organisms including insects 
[19], amphibians [20, 21], mammals [22], bacteria [23], and fish [18]. They are commonly defined as 
having 12-50 amino acids, of which 50% or greater are hydrophobic, and an overall positive net 
charge  [17]. AMPs generally require proteolytic cleavage to produce a mature peptide [24]. These 
peptides are gene-encoded and either constitutively expressed or upregulated during an infection. 
Additionally, transcriptional regulation of AMPs is often species specific and dependent on cell type 
[24, 25]. The expression of these peptides by immune cells usually works in conjunction with other 
components of innate immune response and is commonly associated with inflammation [22, 26, 27].  
The mature peptides, upon contact with cellular membranes, fold into a variety of structurally 
diverse groups including: α-helical, β-sheet, cysteine rich and rare amino acid specific peptides [24, 
25, 28]. While homology exists amongst the structural classification of AMPs, peptides exhibit high 
variability between sequences which is often associated with the multifactorial roles of these 
peptides, as well as the variety of highly specific pathogens each host organism encounters [29, 30]. 
In an effort to better characterize these differences and aid in new therapeutic discovery, a variety 
of antimicrobial databases have been established [31-33]. 
The broad-spectrum activity of AMPs against a wide range of microorganisms including 
Gram positive and Gram negative bacteria, protozoa, fungi, and viruses is well documented [22, 24, 
27-29, 34-40]. Most active AMPs are capable of interacting with bacterial membranes through 
electrostatic and/or hydrophobic interactions, described by four known models [27]. The main direct 
antimicrobial functions are membrane disruption [30] and targeting intracellular components of 
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pathogens [41, 42]. It is generally accepted that positively charged peptides interact directly with the 
negatively charged cellular membranes of bacterial cells through the creation of ion-permeable 
channels, resulting in increase of membrane permeability, which leads to a rapid cell death. It is 
important to note that while AMPs have exhibited a tremendous ability to act as direct antimicrobial 
agents; many limitations to their use do exist. Primarily, AMPs are antagonized by monovalent and 
divalent cations which are commonly present in whole blood or serum [43, 44]. Many of the 
peptides which exhibit low molar concentration killing of bacteria in vitro require selective media 
with low salt concentrations to be effective [45, 46]. Additionally, some naturally produced AMPs 
have shown haemolytic activity towards host cells at concentrations required to be effective against 
pathogens. This is commonly linked to the hydrophobic nature of these peptides [47]. For these 
reasons, AMPs are commonly found in very low molar concentrations within their respective hosts. 
Moreover, while many of these peptides most certainly are bactericidal, in vivo evidence suggests a 
multifunctional purpose for some of these peptides [48].  
Recently, many researchers have been focusing on the immunomodulatory abilities of AMPs 
at physiological concentrations and their influence on innate as well as adaptive immunity. These 
peptides are commonly called host defense peptides (HDPs) referring to their ability to enhance or 
modulate the host immune response to pathogens [24, 46, 48]. In some multicellular organisms, 
primarily mammals, HDPs have been shown to induce both pro- and anti-inflammatory cytokine 
production [49-52], act as chemoattractants of immune cells [36, 51, 53, 54], bind and inhibit 
bacterial LPS function [27, 55, 56], and facilitate the transfer of extracellular DNA/RNA across cellular 
membranes [52, 57-59]. Moreover, the antimicrobial properties of HDPs can be considerably 
affected by the salts and other cellular components present in the blood, organs, mucus, and other 
body fluids [36, 60, 61]. While many AMPs are antagonized by similar conditions, HDPs are unique 
because they are still able to confer protection in vivo, suggesting that while their direct 
antimicrobial activity is mostly lost, their broad range of immunomodulatory activities remain active 
[46, 62-64].  
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1.4 AMPs in fish 
Fish are continually exposed to aquatic pathogens and secrete a wide range of AMPs as a 
primary defense mechanism. Teleost fish express a number of AMPs in mucus and blood as well as a 
variety oforgans that are important for immune defenses including kidney, spleen, intestine, gills, 
reproductive organs and eyes [16-18, 34, 37, 39]. Additionally, many important AMPs have been 
documented in aquaculturally-relevant species (Table 1). 
While some fish AMPs are constitutively expressed, others are up-regulated during 
bacterial infections. For instance, research involving the Atlantic salmon cathelicidins 
(asCATH1 and asCATH2) has shown that asCATH2 was constitutively expressed in a range of 
organs, including anterior and posterior kidney, sampled from healthy Atlantic salmon while 
asCATH1 was not found to be expressed in any tissues [65]. Additionally, fish cathelicidin 
expression studies show that CATH2 cathelicidins are widely expressed whereas CATH1 
cathelicidins are more restricted and often induced by bacterial components [65-67]. 
Similarly, other AMPs have been shown to be inducible by bacterial challenge or bacterially-
derived components [65, 68-73]. The increased expression of AMPs after bacterial induction 
highlights the important role these peptides play as a primary defense mechanism in fish 
innate immunity.  
7 | P a g e  
   
Table 1. A list of some AMPs from important aquaculture species and their putative functions.  
Source organism Peptide  Notes Ref. 
Atlantic cod ( 
Gadus morhua) 
 
CodCath Cathelicidin; Isolated from kidney/spleen; Antimicrobial activity against Gram positive/ Gram 
negative bacteria and fungi; Activity is salt sensitive. 
[74] 
Atlantic cod ( 
Gadus morhua) 
 
Pis1 Piscidin; Antimicrobial activity against both Gram positive and Gram negative bacteria. [75] 
Atlantic cod ( 
Gadus morhua) 
 
Pis2 Piscidin; Antimicrobial activity against Gram negative bacteria. [75] 
Atlantic cod ( 
Gadus morhua) 
 
defB β-defensin; Antimicrobial activity against Gram positive bacteria and stimulatory effect on 
phagocytic activity. 
[76] 
Atlantic salmon 
(Salmo salar) 
asCATH1 Cathelicidin; Antimicrobial activity against both Gram positive and Gram negative bacteria. Increased 
transient expression of IL-8 in PBL in vitro. 
[65, 66] 
Atlantic salmon 
(Salmo salar) 
asCATH2 Cathelicidin; Antimicrobial activity against both Gram positive and Gram negative bacteria. Increased 
transient expression of IL-8 in PBL in vitro. 
[65, 66] 
Atlantic salmon 
(Salmo salar) 
SAMP H1 Peptide derived from histone H1; Expressed in skin mucus as antibacterial agent. [77, 78] 
Rainbow trout 
(Oncorhynchus 
mykiss) 
Oncorhyncin  
II 
C-terminal fragment of histone H1; Antimicrobial activity against both Gram positive and Gram 
negative bacteria. Potentially important role in mucosal defence.  
[79] 
Rainbow trout 
(Oncorhynchus 
mykiss) 
Oncorhyncin  
III 
Cleavage product of the non-histone chromosomal protein H6; Antimicrobial activity against both 
Gram positive and Gram negative bacteria. Potentially important role in mucosal defence. 
[80] 
Rainbow trout 
(Oncorhynchus 
mykiss) 
Hepcidin Hepcidin; role in iron homeostasis during inflammation as well as acting as an antimicrobial peptide [81] 
Rainbow trout 
(Oncorhynchus 
mykiss) 
omDB-2 β-defensin; Induced in skin, gills, and gut tissue after in vivo bacterial challenge. Upregulated after 
head kidney primary leucocyte cultures were stimulated with (polyI:C) in vitro. 
[68] 
Rainbow trout 
(Oncorhynchus 
omDB-3 β-defensin; Induced in skin, gills, and gut tissue after in vivo bacterial challenge. Upregulated after 
head kidney primary leucocyte cultures were stimulated with (polyI:C) in vitro. 
[68] 
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mykiss) 
Rainbow trout 
(Oncorhynchus 
mykiss) 
omDB-4 β-defensin; Induced in skin, gills, and gut tissue after in vivo bacterial challenge. Upregulated after 
head kidney primary leucocyte cultures were stimulated with (polyI:C) in vitro. 
[68] 
Tilapia 
(Oreochromis 
mossambicus) 
 
TH1-5 Hepcidin; Induced by (polyI:C)  in liver and head kidney tissue after in vivo after in vivo i.p injection. [82] 
Tilapia 
(Oreochromis 
mossambicus) 
 
TH2-2 Hepcidin; Induced in head kidney tissue after in vivo i.p injection. No noted antimicrobial ability. [82] 
Tilapia 
(Oreochromis 
mossambicus) 
 
TH2-3 Hepcidin; Induced by LPS in liver tissue after in vivo i.p injection. [82] 
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   The direct antimicrobial and bactericidal functions of fish AMPs is well 
documented [18, 65, 66, 72, 75, 83-85], with most showing modest in vitro inhibition of 
both Gram negative and Gram positive strains. Like their mammalian counterparts, it is 
generally accepted that the positively charged nature of fish AMPs facilitates binding to 
negatively charged molecules or components in bacterial membranes and cause direct lysis 
through pore formation or inactivation of biological properties associated with the 
membranes. Piscidin, an antibacterial peptide isolated from the mast cells of hybrid striped 
bass (Morone saxatilis x M. chrysops) has been shown to remain unstructured in water but 
had high a-helix content in dodecyl-phosphocholine (DPC) micelle which mimics bacterial 
membranes. Additional multichannel and single channel experiments were used to show 
that this peptides act through the permeabilization of the bacterial membrane via pore 
formation [86]. This non-specific but highly functional mechanism for membrane disruption 
allows AMPs to destroy microbes at micromolar concentrations. Moreover, some fish AMPs 
have shown antiviral and antifungal properties. Tilapia (Oreochromis mossambicus) hepcidin 
1-5 (TH 1-5) exhibited antiviral activities against nervous necrosis virus (NNV) in vitro [87]. 
Epinecidin-1, an AMP isolated from orange-spotted grouper (Epinephelus coioides), along 
with TH 1-5 were also shown to significantly decrease grouper larvae mortality after co-
injection with NNV. Furthermore, re-challenge with the virus after 30 days in the co-treated 
group showed high survival [88]. Piscidin-2 (P2) isolated from hybrid striped bass (Morone 
saxatilis × M. chrysops) exhibited potent antifungal activity and caused fungal membrane 
damage against human pathogenic fungi in vitro [89]. This has led to discussion of its 
potential application in human dermatology [16]. 
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  In addition to their anti-infective capabilities, some fish AMPs possess 
immunomodulatory properties similar to their mammalian counterparts. Previous work by 
our group has demonstrated that Atlantic salmon cathelicidins (asCATH1 and asCATH2) 
stimulate the transient expression of the IL-8, an important chemotactic chemokine, in vitro 
in peripheral blood leukocytes [65]. Tilapia hepcidin (TH2-3) was shown to down-regulate 
the proinflammatory cytokines TNF-α, interleukin (IL)-1α, IL-1β, IL-6, and the prostaglandin 
synthesis gene, cyclooxygenase (COX)-2 in LPS-stimulated mouse macrophages [90] and 
modulate protein kinase C (PKC)-associated proteins in RAW264.7 macrophages [91]. In 
both studies, the powerful ability of TH2-3 to suppress LPS-induced proinflammatory 
cytokines was shown. Zebrafish (Danio rerio) β-defensin 2 (zfBD2) coupled with a plasmid 
delivery system was shown to trigger the activation of the type 1 IFN-system, induce the 
transcription of TNF-α and IL-1β which are both involved in inflammation, increased the 
presence of major histocompatibility complex class II (MHC-II) transcripts, enhanced the 
cytotoxic cell response, and mediated the recruitment of Th cells at the injection site [92]. In 
contrast, the plasmid alone did not elicit these responses. Additionally, epinecidin-1 was 
shown to modulate the expression of immune-responsive genes, decreased TNF-α 
production, and significantly increased the survival rate of mice in vivo [93]. These 
mammalian studies provide preliminary evidence that fish AMPs are capable of modulating 
immune responses in higher vertebrates. Furthermore, they exhibit the potential of fish 
AMPs as more than mere antimicrobial compounds but also as immunostimulants and 
potential adjuvants.  
Despite the many positive aspects of natural AMPs, many barriers still exist in their road 
to therapeutic application. The development of these peptides as systemic therapeutics has 
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been hampered by their potential for toxic side effects (cytotoxicity) and liability to 
proteolytic degradation [29, 43, 46]. The high antibacterial activity of natural AMPs in vitro is 
often correlated with increased haemolytic activity, or the ability to lyse eukaryotic cells [48, 
94].  Moreover, the antimicrobial activity of AMPs is antagonized to variable extents by 
cellular and physiological components (cationic salts) in mucus, blood, and tissue [24, 28, 29, 
45, 46]. Consequently, most clinical trials to date have focused on AMPs for topical 
applications. Furthermore, a major deterrent to natural peptide production is the cost 
associated with their production and the purity required for their therapeutic application. 
Currently, solid-phase chemical synthesis and to a lesser extent recombinant methods are 
used to produce AMPs synthetically [24, 95, 96]. These methods favour short peptides with 
relatively simple structural features. However, many natural AMPs are quite long (12-50 
amino acids), have diverse structural components such as several disulphide bonds which 
are difficult to recreate through chemical synthesis, and many require post-transcriptional 
modification to produce functional mature peptides [43, 96, 97].  
1.5 Rationale for synthetic peptide selection 
In recent years, improved peptide synthesis methods and large, continually updated 
AMP databases have allowed for the production of synthetic AMPs with many superior 
characteristics to their parent peptides [31-33, 98]. The parameters, methodology, and 
approaches used to conceptualize and develop synthetic peptides are extremely diverse and 
entirely dependent on the intended application of the final peptide (Figure 3). Moreover, 
these methods are rapidly evolving in stride with new production technology. General 
approaches adopted in the design of synthetic AMPs include sequence modifications from 
naturally occurring template peptides, de novo minimalist design of amphipathic peptides, 
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and the use of computer-assisted virtual screening to aid in the identification of new lead 
sequences [97, 99]. The majority of the peptides used in this thesis were created using these 
methodologies. Additionally, many of the peptides also possess the potent properties of 
cationic cell-penetrating peptides.  P9-4 was developed from the Trp-rich peptide Pac-525 
and P11-5/ P11-6 were developed using  BP76 as a template [100, 101]. These peptides 
exhibit improved stability in the presence of salts, reduced cytotoxicity and substantially 
improved MICs compared to their parent peptides [102]. K6L2W3 and K7LW3 were also 
designed based on a Trp-rich peptide, Indolicidin [103]. These peptides showed high cell 
specificity towards bacterial cells in a previous study. Moreover, K6L2W3 exhibited anti-
inflammatory activity by inhibited LPS-induced nitric oxide synthase (iNOS) mRNA 
expression and the release of nitric oxide (NO) following LPS stimulation in RAW264.7 cells 
in vitro [103]. Pep-1K was modelled after the cell-penetrating peptide Pep-1 and showed 
improved MICs compared to the reference peptide [104]. PG-1 was derived from porcine 
leukocytes and represents the only β-sheet peptide evaluated in this thesis. Previous studies 
involving PG-1 showed its ability to neutralize the effect of the Neisseria 
meningitidis endotoxin through significantly decreased  TNF-α release from THP-1 cells  and 
nitric oxide release from RAW 264.7 cells [50], as well as its potent antimicrobial capabilities 
in vitro and in vivo efficacy in mice trials [105]. 
However, HHC-10 was developed using an entirely different method than the 
previous mentioned peptides. HHC-10 was the product of advanced in silico predictive 
modelling and artificial intelligence [106]. In this study, Cherkasov and his colleagues used a 
chemo-informatics approach called quantitative structure-activity relationship (QSAR) and 
Artificial Neural Networks, a powerful machine learning technique, to assess and predict the 
antibiotic activity of 100,000 virtual peptides based on two large random 9-amino-acid 
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peptide libraries. HHC-10, and one other peptide, represent the top quartile of predicted 
activities and were selected to undergo additional testing. The results of this study showed 
that HHC-10 was effective against many strains of multidrug resistant bacteria with activities 
that equal or outperform conventional antibiotics. Additionally, it was shown to protect 
against Staphylococcus aureus infections in animal models [106]. 
Taken as a whole, all of these cationic synthetic peptides represent novel and 
interesting candidates for therapeutic applications in fish-related disease. In Chapters 2 & 4 
of this thesis, the potential use of these peptides is explored in greater depth. 
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Figure 3. Overview of strategies employed in the design and optimization of synthetic AMPs.
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1.6 Thesis aims   
The major aim of this research is to investigate the dynamic role AMPs play in the innate immune 
system of fish, both as direct antimicrobial agents and in their ability to modulate immune response. 
Research in the following chapters has been focused on the following key objectives: 
• Investigate the potential immunomodulatory capabilities of Atlantic salmon cathelicidins 
(asCATH1 and asCATH2) on S. salar leukocyte populations (Chapter 2) 
• Investigate the potential therapeutic applications of novel synthetic cationic peptides on S. 
salar varying leukocyte populations 
o Assess the direct antimicrobial capabilities of synthetic peptides against a range of 
aquatic pathogens in vitro and establish MIC for each (Chapter 3) 
o Assess the immunostimulatory and immunmodulatory capability of synthetic 
peptides and effect on S. salar leukocyte populations (Chapter 3 and 4) 
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Chapter 2: Atlantic salmon cathelicidin (asCATH2) increases 
phagocytosis, cell proliferation and respiratory burst in 
Atlantic salmon (Salmo salar L.) head kidney leukocytes
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2.1 Introduction  
Cathelicidins are a class of AMPs (AMPS) which play an important and 
multifunctional role in the innate immune system of multicellular organism [26, 28, 35]. 
These host defense peptides consist of a homologous N-terminal signal sequence and 
proregion, a cathelin-like domain from which their name is derived, and a variable C-
terminal antimicrobial domain  [107]. Peptides are stored in immune cells as inactive 
precursors (prepropeptides) which undergo proteolytic cleavage during an infection to 
release a mature peptide with cationic and hydrophobic attributes [26, 107]. While the 
resultant antimicrobial peptide is highly variable in size and sequence composition even 
within species, all peptides have an overall positive net charge [17, 26, 65, 107]. These 
amphipathic peptides function as natural antibiotics produced by the host, disrupting the 
cell membrane of invading bacteria during an infection [65, 66]. They are able to combat a 
wide variety of pathogens including Gram negative and Gram positive bacteria, parasites, 
fungi, and viruses [28]. While the mammalian cathelicidins are the most widely studied, this 
class of peptides exists in a wide variety of insects [22], reptiles [108], and fish [66, 107, 109] 
with new organisms constantly being added to the list. 
 In addition to their antimicrobial capacity, cathelicidins work in conjunction with 
other inflammatory cells and possess a diverse range of immunomodulatory features. These 
features include the ability to recruit host immune cells to the site of infection [22, 27, 36, 
48], stimulate or inhibit cytokines and chemokines from a variety of different cell types [24, 
36, 110], and alter host gene expression [65, 111-114]. More recently, cathelicidins have 
been shown to bind and facilitate the uptake of extracellular components into host immune 
cells during prolonged infections [57, 59, 115]. These functions allow for rapid identification 
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and destruction of pathogens and highlight the multifaceted role of AMPs in the innate 
immune system.  
While a great deal of information can be found concerning the role of cathelicidins in 
mammals [26, 28, 116], cathelicidins have only recently been identified and characterized in 
fish [26, 66, 74, 109]. Many of the species which have been characterized are commercially 
relevant and include rainbow trout (Oncorhynchus mykiss) [109], Atlantic salmon (Salmo 
salar) [66], Atlantic cod (Gadus morhua ) [67, 107], and Arctic charr (Salvelinus alpinus) [74, 
107].  Previously, our group explored the role of these peptides during an infection with Y. 
ruckeri. AsCATH2 was shown to be constitutively expressed in healthy Atlantic salmon while 
asCATH1 was not, and the expression of both was induced following bacterial challenge. 
Additionally, it was demonstrated that Atlantic salmon cathelicidins stimulated the 
expression of chemokine interleukin-8 in peripheral blood leukocytes (PBLs) [65]. Recent 
evidence has suggested that cathelicidins in mammals have the ability to promote 
phagocytosis by leukocytes [64]. It remains unclear if this is a function limited to mammalian 
cathelicidins or to the class of peptides as a whole.  
 The aim of this study was to assess the in vitro immunomodulatory ability of 
asCATH1 and asCATH2 using head kidney leukocytes in Atlantic salmon (Salmo salar). 
Functional assays were utilized to assess the direct stimulatory capacity of these peptides on 
phagocytosis, cell proliferation, and respiratory burst. 
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 2.2 Materials and Methods 
2.2.1 Ethics statement 
All work involving animals was approved by the University of Tasmania Animal Ethics 
Committee in accordance with the Australian Code of Practice for the Care and Use of 
Animals for Scientific Purposes. 
2.2.2 Reagents 
Oligodeoxynucleotides purchased from Sigma Genosys (Castle Hill, NSW, Australia) 
were phosphorothioated to increase their resistance to nuclease degradation [117]. The 
sequence for CpG-ODN 1668 was (TCCATGACGTTCCTGATGCT). This Oligodeoxynucleotide 
sequence was selected based on its effective use in Atlantic salmon, rainbow trout, other 
teleost fish, and murine studies [118-121]. 
The two salmonid peptides (asCATH1 and asCATH2) were chemically synthesised by 
Auspep (Tullamarine, Victoria, Australia). These peptides corresponded to the first 36 amino 
acids of each mature peptide of the previously reported Atlantic salmon cathelicidins [66]. 
The first peptide, referred to as asCATH1 (RRSQARKCSRGNGGKIGSIRCRGGGTRLGGGSLIGR), 
had a molecular weight of 3685 g/mol and corresponds to residues 145 to 180 of the S. salar 
cathelicidin (acc. #: AAW55907). The second, referred to as asCATH2 
(RRGKPSGGSRGSKMGSKDSKGGWRGRPGSGSRPGFG), had a molecular weight of 3632 g/mol 
and corresponds to residues 150 to 185 of the S. salar cathelicidin-derived antimicrobial 
peptide 2 precursor (acc. #: AAT44537). These cathelicidin derived peptides and their 
corresponding concentrations were selected based on their suggested antimicrobial and 
immunomodulatory role in a previous study [65]. 
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2.2.3 Fish 
Atlantic salmon weighing approximately 200-300 g were maintained in a 3000L 
freshwater water re-circulating tank with biofilter at the School of Aquaculture, University of 
Tasmania, Launceston, Australia. Fish were euthanized with a lethal dose of anaesthetic at 
5 g/L  Aqui-S® (Aqui-S NZ Ltd, Lower Hutt, New Zealand) prior to head kidney isolation. 
2.2.4 Isolation of head kidney leukocytes  
Head kidney leukocytes were isolated as previously described [122]. Briefly, head 
kidney was aseptically removed from each fish and repeatedly passed through a 100 µM 
sterilized metal mesh using L-15 medium containing 1% penicillin and streptomycin (P/S) 
(Sigma), 0.2% heparin (20 U/mL) (Sigma). The resulting cell suspensions were placed on a 
34/54% Percoll (Sigma) gradient and centrifuged at 400 g for 40 min at 4°C. The interface 
was harvested and washed twice in phosphate buffered solution (PBS, Sigma) at 400 g for 5 
min in previously mentioned media. Cells were quantified using a haemocytometer by 
trypan blue exclusion for use in their respective assays. 
2.2.5 Phagocytosis assay 
Phagocytosis was assessed using methods previously described with modification 
[123]. Briefly, cells were seeded in 96-well plates at a density of 1 x 107 cells per well, and 
allowed to adhere at 18°C for 3 h. Wells were then washed three times with L-15 medium 
containing 1% penicillin and streptomycin to remove any non-adherent cells. Cells were 
stimulated with asCATH1 (5µM), asCATH2 (5µM), or CpG-ODN 1668 (5µM) for 4 h at 18°C. 
Control leukocytes were incubated with L-15 medium alone. After the incubation period, 20 
µL Congo red-stained yeast cells (107 cells/mL) were added to each well. To monitor 
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phagocytosis, two pictures were taken randomly for each well using  a Cannon 600D Digital 
SLR with an optical adapter on a light microscope at given time points. The phagocytic 
activity (PA) was determined by the percentage of cells with engulfed yeast cells (PA = 
number of phagocytic cells with engulfed bacteria/number of phagocytes). The phagocytic 
index (PI) was determined by the number of engulfed yeast cells per cell (PI = number of 
engulfed yeast/phagocytic cells). 
2.2.6 Respiratory burst activity assay 
Respiratory burst activity was assessed by nitro blue tetrazolium (NBT) (Sigma) 
reduction to formazan after stimulation of cells as previously described [123]. Briefly, cells 
were isolated and stimulated for 4h at 18°C in 96-well plates as stated above. Untreated 
leukocytes were used as the negative control and leukocytes treated with phorbol myristate 
acetate (PMA) (100 ng/mL) as a positive control. After stimulation, the cell monolayer was 
washed twice with PBS to remove any residual stimulant and 100 µL of NBT solution (1 
mg/mL in L-15) was added per well. Cultures were then incubated at 18°C for 1 h. After 
incubation, cells were fixed with methanol after the removal of the NBT solution. Cells were 
then air dried for 20 min then washed again to remove residual methanol. Finally, 120 µL 
2M KOH and 140 µL of DMSO (Sigma) were added to each well and the optical density was 
measured with an Infinite M200 Pro microplate reader (Tecan) at 620 nm.  
2.2.7 Cell proliferation assay 
 Cell proliferation was assessed by measuring total nucleic acid content of lysed cells 
after stimulation treatments using a fluorometer. Briefly, cells were seeded in 96-well plates 
at a density of 1 x 105 cells per well, and allowed to adhere at 18°C for 3 h. Wells  were then 
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washed three times with L-15 medium containing 1% penicillin and streptomycin and 10% 
to remove any non-adherent cells. Cells were stimulated with asCATH1 (5µM), asCATH2 
(5µM), or CpG-ODN 1668 (5µM) for 5 days at 18°C. Control leukocytes were incubated with 
L-15 medium alone. Cells were immediately frozen after stimulation. Total nucleic acid was 
extracted as previously described with modification [124]. Briefly, previously stimulated 96-
well plates were defrosted and 300 µL nucleic acid extraction buffer (4M urea, 1% SDS, 0.2 
M NaCl, 1 mM sodium citrate pH 7.5) containing 20 U of proteinase K (Bioline) per sample 
was added to each well. 96-well plates were then placed on ice and allowed to digest for 30 
min. Samples were transferred from their wells into fresh 1.5 mL microcentrifuge tubes. 
Protein, cellular debris, and detergent were removed by centrifugation in 7.5M ammonium 
acetate at 14,000 x g for 5 min, and nucleic acids were recovered by isopropanol 
precipitation at 16,000 x g for 10 min followed by an ethanol wash of the nucleic acid pellet. 
Complete removal of RNA was ensured by treatment with 4 units RNase A (Sigma) for 30 
min at 37°C. Samples were then resuspended in molecular water and quantified using a 
Qubit fluorometer (Invitrogen) using the manufacturer’s protocol. 
 
2.2.8 Statistical analysis 
Statistical analysis was carried out using GRAPHPADTM PRISM version 5.00 for 
WINDOWS® (GraphPad Software). Differences between groups were determined using a 
one-way ANOVA with a Tukey posthoc test. Data were subject to a Shapiro–Wilk's test for 
normality and a Levene's test for equality of variances to satisfy the assumptions required 
for an ANOVA.  Results were considered significant if P < 0.05. 
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 2.3 Results 
2.3.1 Phagocytosis assay 
Phagocytic activity of head kidney leukocytes stimulated with asCATH1 (5 µM), 
asCATH2 (5 µM), CpG-ODN 1668 (5 µM) or an untreated cell control differed significantly (F 
[3, 8] = 36.06, P < 0.0001; Figure 4A). A Tukey’s post-hoc analysis of the groups indicated that 
there was a significant increase in the phagocytic activity of asCATH2 compared to the 
control and asCATH1 (P < 0.05). In addition CpG-ODN 1668 had a significantly higher 
phagocytic activity than all other treatments (P < 0.05). There was no significant effect on 
phagocytic index by any of the treatments (F [3, 8] = 0.6703, P =0.5938; Figure 4B). 
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Figure 4. Phagocytic activity (a) and phagocytic index (b) of Atlantic salmon (S. salar) head 
kidney leukocytes stimulated with asCATH1 (5 µM), asCATH2 (5 µM), or CpG-ODN 1668 (5 
µM). The phagocytic activity (PA) was determined by the percentage of cells with engulfed 
yeast cells (PA = percentage of phagocytic cells with engulfed bacteria). The phagocytic 
index (PI) is determined by the number of engulfed yeast cells per cell (PI = number of 
engulfed yeast/phagocytic cells). Control leukocytes were incubated with medium alone. 
Data shown are the means ± SE of quadruplicate HKL samples assayed from 3 fish. Different 
superscript letters indicate significant differences between the groups (P <0.05). 
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2.3.2 Respiratory burst assay 
Respiratory burst of head kidney leukocytes stimulated with asCATH1 (5µM), 
asCATH2 (5 µM), CpG-ODN 1668 (5 µM), PMA (100 ng/mL), or an untreated cell control 
differed significantly between treatments (F [4, 10] = 18.70, P = 0.0001; Figure 5). A Tukey’s 
post-hoc analysis of the groups indicated that there was a significant increase in the NBT 
reduction of asCATH2 compared to the control (P < 0.05). CpG-ODN 1668 had a significantly 
higher NBT reduction than all other treatments (P < 0.05) except the positive control, PMA, 
which had significantly greater NBT reduction than all other treatments (P < 0.05). 
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Figure 5. Respiratory burst activity of Atlantic salmon (S. salar) head kidney leukocytes 
stimulated with asCATH1 (5 µM), asCATH2 (5 µM), or CpG-ODN 1668 (5 µM). Control 
leukocytes were incubated with medium alone and positive controls were treated with PMA 
(100 ng/ml). Data shown are the means ± SE of quadruplicate HKL samples assayed from 3 
fish at 620 nm after 60 min incubation. Different superscript letters indicate significant 
differences between the groups (P <0.05). 
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2.3.3 Cell proliferation assay 
Cell proliferation of head kidney leukocytes stimulated with asCATH1 (5µM), 
asCATH2 (5 µM), CpG-ODN 1668 (5 µM), or an untreated cell control differed significantly 
between treatments (F [3, 18] = 80.81, P < 0.0001; Figure 6). A Tukey’s post-hoc analysis of the 
groups indicated that there was a significant increase in total DNA yield of cells treated with 
asCATH2 compared to the control and asCATH1 (P < 0.05). Cells stimulated with CpG-ODN 
1668 had a significantly higher total DNA yield than all other treatments (P < 0.05). 
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Figure 6. Cell proliferation of Atlantic salmon (S. salar) head kidney leukocytes stimulated 
with asCATH1 (5µM), asCATH2 (5µM), or CpG-ODN 1668 (5µM) for 5 days. Control 
leukocytes were incubated with medium alone. Data shown are the means ± SE of 
quadruplicate HKL samples assayed from 3 fish. Different superscript letters indicate 
significant differences between the groups (P <0.05). 
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2.4 Discussion  
While the antimicrobial properties of cathelicidins are well described, recent 
research suggests that their ability to act as chemotactic agents [36] and 
immunomodulators [46, 48, 63, 125] may be the most relevant function in the context of 
bacterial infections. In this study, we demonstrated that the Atlantic salmon cathelicidin, 
asCATH2, was capable of improving leukocyte phagocytic activity and respiratory burst in 
vitro. Conversely, asCATH1 had minimal stimulatory activity in vitro. It has been well 
established that fish phagocytes possess oxidative burst responses comparable to those 
exhibited by mammalian phagocytes and that phagocytosis triggers the activation and rapid 
release of reactive oxygen species (ROS) via the NADPH oxidase complex [37]. Therefore, 
the increased phagocytic activity induced by asCATH2 correlates well with the improved 
respiratory burst seen when cells were stimulated with the same concentration of asCATH2. 
Moreover, research involving LL-37, the human cathelicidin, has shown it is capable of 
inducing a prophagocytic response at low concentrations of peptide but not at higher 
dosages despite a lack of cytotoxic activity on macrophages. In another study, LL-37 has 
been shown to induce the production of ROS in murine and human macrophages[50]. While 
the mature peptides of LL-37 and asCATH2 differ substantially in amino acid composition 
and structure, they are both able to elicit similar biological functions on host immune cells. 
In addition to improved phagocytic function, asCATH2 induced increased cell 
proliferation in leukocytes stimulated for 5 days whereas asCATH1 did not vary significantly 
from the controls. Previous work by our group has demonstrated that Atlantic salmon 
cathelicidins stimulated the transient expression of the interleukin-8, an important 
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chemotactic chemokine, in peripheral blood leukocytes. In these studies, asCATH2 was 
found to be constitutively expressed in healthy fish and was upregulated to a greater extent 
than asCATH1 after bacterial challenge. Conversely, asCATH1 was not expressed in any 
organ, prior to bacterial challenge. This pattern of expression for CATH1 and CATH2 
peptides has been shown to exist in other salmonids as well [66, 107, 126].  Additionally, 
asCATH2 showed no haemolysis towards erythrocytes in either serum or conventional 
media and lower antibacterial activity than asCATH1[65]. The upregulation during bacterial 
infections and minimized bactericidal activity may suggest that asCATH2 serves to modulate 
immune-competent cells during bacterial infections rather than function as a direct 
antimicrobial defense mechanism. Similarly, it has been suggested that LL-37 functions as an 
immunomodulator in vivo because it is produced constitutively at low concentrations (2–5 
µg/ml) at mucosal surface and in most bodily fluids and lacks antimicrobial abilities at high 
concentrations (100 µg/ml) in tissue culture media[64]. Additionally, LL-37 has been shown 
to increase cell proliferation in human epithelial cell lines and promote wound healing [62, 
127]. However, the question remains as to why asCATH2 is capable of immunomodulatory 
functions whereas asCATH1 is not. While an overwhelming amount of evidence suggests 
that AMPs interface directly with bacterial membranes to exhibit their antimicrobial action, 
this does not explain the diverse range of non-membrane mechanisms and alternative 
signaling cascades that some AMPs are able to elicit. Moreover, while difference in mature 
peptide structure exists between asCATH1 and asCATH2, amino acid composition alone is 
not a hallmark of bioactivity. A previous study suggests that the AMP membrane 
interactions cannot be explained by a particular sequential amino-acid pattern or motif but 
rather a combination of features, both structural and physicochemical [95].  
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Currently, information regarding the expression of these cathelicidins in salmonids 
has been isolated down to specific tissues but not specific cell types [65, 66, 107]. While the 
limited amount of information regarding AMPs, their cell-associated ligands, and 
immunological cascade signalling in salmonids makes it difficult to ascertain the specific 
functions of fish cathelicidin, the evolutionary status of teleost fish in relation to other 
vertebrates allows for speculation of potential cellular targets. In mammalian studies, 
cathelicidin expression has been closely related to TLR- activation [13, 128]. TLRs play an 
important role in recognizing specific microbial components derived from pathogens 
including bacteria, fungi, protozoa and viruses. These receptors recognize PAMPs through 
cell surface TLRs or through intracellular TLRs (Figure 7). Further, they play an important role 
in recognition of self and non-self and their signalling initiates a complex cascade of innate 
and adaptive immune responses. 
 
Figure 7. TLR family members recognize specific patterns of microbial components. Image 
source: [14]. 
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Cathelicidins are known to both inhibit and activate inflammatory responses via TLR 
signaling. The bovine cathelicidin BMAP-28 is capable of suppressing the proinflammatory 
response induced by LPS in RAW 264.7 macrophages by blocking LPS-induced cytokine gene 
expression [129]. However, BMAP-28 alone was cable of inducing upregulation of IL-1β gene 
expression in these cells, suggesting it has the capacity to activate selected cellular 
pathways through direct effects on macrophages [129]. The guinea pig α-helical cathelicidin 
CAP11 was shown to suppress the production of anandamide, a mediator of endotoxic 
shock, in LPS stimulated RAW 264.7 macrophages in a dose dependant manner [130]. 
Additionally, a previous study involving CAP11 showed that this peptide suppressed LPS-
induced TNF-α mRNA and protein expression when analysed by Northern and Western blot 
[131]. Taken as a whole, these studies indicate that cathelicidins play an integral role in 
suppressing bacterially-derived inflammation through mitigation at the cellular level. Future 
work involving the salmonid cathelicidins could emulate these experiments to see if these 
peptides exhibit similar functions to other vertebrate cathelicidins. Studies could look into 
the differential expression of these peptides after the administration of a variety of different 
microbial compounds such as CpG-ODN, LPS, flagellin, and poly(I:C) in Atlantic salmon, as 
this has already been done in vitro in CHSE-214 cells [67]. Future studies should focus on 
identifying the specific pathways elicited by these peptides, establish whether or not this is 
dose-dependent, and screen a larger selection of immune-related genes than previous 
studies. These studies could provide invaluable insight into the role of cathelicidins during 
an innate immune response in salmonids. 
In this study, CpG-ODN 1668 was utilized as a positive control due to its strong 
immunostimulatory ability. CpG-ODN 1668 exhibited the highest level of stimulation 
30 | P a g e  
   
P a g e  | 31 
 
significantly increasing phagocytosis, respiratory burst, and cell proliferation. CpG-ODN 1668  
is a class B oligodeoxynucleotide containing a full phosphorothioate backbone and is known 
for the ability to strongly activate B cells in mammals [132]. Previous studies involving class 
B CpG-ODNs showed their ability to induce increased cell proliferation in Atlantic salmon 
head kidney leukocytes [133] and exhibit their immunostimulatory ability in vivo [119]. 
Furthermore, CpG-ODN has been shown to enhance phagocytic ability and ROS production 
by head kidney phagocytes when injected in carp (Cyprinus carpio L.) in vivo [134].  
2.5 Conclusion 
In conclusion, this study demonstrated that asCATH2 and CpG-ODN 1668 were 
capable of stimulating head kidney leukocytes to improve phagocytic activity, respiratory 
burst, and cell proliferation at micromolar concentrations while asCATH1 did not have any 
significant effect. This data further support the notion that asCATH2 may serve a 
multifaceted biological role during bacterial infections and that asCATH1 is induced after 
bacterial stimulation and primarily functions as a lytic peptide. Additionally, these data 
provide further evidence of the functional differences which exist between Atlantic salmon 
cathelicidins. Moreover, this study is believed to be the first to report that a fish cathelicidin 
is capable of increasing phagocytosis, cellular proliferation, and respiratory burst in head 
kidney leukocytes. While the mechanisms and stimulation pathways which govern this 
reaction remain unknown, these functional assays suggest that cathelicidins play an 
important role in bridging innate and adaptive immunity in salmonids.  
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Chapter 3: Short synthetic cationic peptides exhibit 
antimicrobial activity and immunomodulatory functions in 
vitro in Atlantic salmon (Salmo salar)
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3.1 Introduction 
While natural sources of AMPs exist, synthetic analogs of these peptides have been 
created by the removal and or substitution of amino acids which correspond to peptide 
hydrophobicity and enhanced biological activities [44, 135]. Additionally, naturally occurring 
AMPs are larger in size and create several issues related to synthesis, metabolic stability and 
cost of production [136]. The purpose of this work is to characterise the antimicrobial and 
immunomodulatory properties of selected synthetic peptides (Table 2) against known fish 
pathogens in physiologically relevant environments. In previous trials comparing naturally 
produced AMPs, these synthetic peptides have shown high target specificity [103], low 
cytotoxicity to the host [102] , low minimum inhibitory concentrations [102, 103], and 
improved stability in saline environments [102, 105].  
3.2 Materials and Methods 
3.2.1 Ethics statement 
All work involving animals was approved by the University of Tasmania Animal Ethics 
Committee in accordance with the Australian Code of Practice for the Care and Use of 
Animals for Scientific Purposes. 
3.2.2 Fish Sampling 
Atlantic salmon (Salmo salar) were obtained from a recirculation tank-based 
population of fish maintained at the School of Aquaculture, University of Tasmania 
(Launceston, Tasmania, Australia). Fish were euthanized with a lethal dose of anaesthetic at 
34 | P a g e  
   
P a g e  | 35 
 
1 g/L  Aqui-S® (Aqui-S NZ Ltd, Lower Hutt, New Zealand) and blood was collected for serum 
and PBL assays. 
3.2.3 Peptide synthesis 
All peptides listed in Table 2 were synthesized using the solidphase method and 
standard 9-fluorenyl methoxy carbonyl chemistry and purified to >95% purity using reverse-
phase high-pressure liquid chromatography by Life Research Australia. Certificates of 
analysis provided with each peptide displayed HPLC chromatogram and mass spectral 
analysis identifying the purity to be greater than 95% and identity of each peptide.  
 
Table 2. Summary of synthetic AMPs used in this study. 
Peptide Sequence Molecular weight  
(g/mol) 
Purity (%) Ref. 
P9-4 Ac-KWRRWIRWL- NH2 1440.78 95.50 [102] 
P11-5 Ac-GKLFKKILKIL- NH2 1341.80 96.89 [102] 
P11-6 Ac-KKLIKKILKIL- NH2 1378.91 96.97 [102] 
HHC10 Ac-KRWWKWIRW- NH2 1485.82 99.27 [106] 
K6L2W3 Ac-KLWKKWKKWLK-NH2 1613.09 96.84 [103] 
K7LW3 Ac-KLWKKWKKWKK-NH2 1628.10 95.72 [103] 
PG-1 Ac-RGGRLCYCRRRFCVCVGR-NH2 2201.68 96.54 [105] 
Pep-1-K Ac-KKTWWKTWWTKWSQPKKKRKV-NH2 2886.51 97.34 [34, 104]  
 
 
3.2.4 Bacterial culture conditions 
Aeromonas hydrophila, Escherichia coli (ATCC 25922), Pseudomonas aeruginosa, and 
the Tasmanian O1b serotype of Yersinia ruckeri (UTYR 001A) were used to test the 
antibacterial activities of the selected AMPs. Aeromonas hydrophila and Yersinia ruckeri 
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represent potential fish pathogens and E. coli and P. aeruginosa have known MICs for these 
peptides [102]. Bacteria were grown at 20°C in 4 mL of Mueller-Hinton broth (MHB) until 
they reached mid-log phase then 1 mL of the log-phase suspension was centrifuged at 1,000 
xg for 5 minutes at room temperature. The supernatant was removed and the bacterial 
pellet was resuspended in 1 mL of one quarter strength (0.25x) MHB. The suspension was 
diluted 1:1000 by adding 10 mL to 10 mL of 0.25x MHB to give a final working suspension of 
approximately 1 x105 cells/mL.  
3.2.5 Antimicrobial and salt tolerance assay 
A broth microdilution assay was used to measure the antimicrobial activity and salt 
tolerances of the selected synthetic peptides as previously described [137]. In brief, bacteria 
were grown to a mid-log phase in MHB and diluted to 1x105 cells/mL. Each peptide was 
serially diluted in sterile water to give final concentrations of 800, 400, 200, 100, 50, 25, 12.5 
and 6.25 µM. 90 µl of the 1:1000 bacterial suspension was combined with 10 µl of each 
peptide dilution in a flat bottom 96 well polystyrene microtitre plate so that final peptide 
concentrations were 80, 40, 20, 10, 5, 2.5, 1.25 and 0.63 µM. To determine the resistance of 
the AMPs against salt, NaCl in varying concentrations (0-300 mM) was added to the 
samples. Each species had four technical replicates. Plates were incubated at 20°C for 18 h 
then absorbances were read at 600 nm. Positive controls contained bacterial suspension 
with 10 µL of water and negative controls contained 0.25x MHB media with no bacterial 
cells. Microbial growth was determined by optical density measurement at 600 nm using a 
microplate reader (Tecan GENios). The MIC was defined as the lowest concentration of 
peptide that reduced bacterial growth by more than 50% compared to positive control wells 
[66, 109, 138]. 
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The synthetic peptides P9-4, P11-5, P11-6, and PG-1 were chosen as candidates to 
examine interactions between peptide and serum using a serum microdilution assay due to 
their relatively low MIC values in the previous experiments. To attain Atlantic salmon serum, 
45 mL of previously extracted whole blood was subdivided into 15 mL tubes, incubated at 
room temperature for 30 minutes, and then placed at 4°C overnight. Coagulated blood was 
centrifuged at 900 xg for 10 minutes at 4°C. Serum was collected from above the cell pellet 
of each tube and pooled into a 50 mL tube. Serum was then heat inactivated using a 
previously described method [61]. 
 The pathogen selected for this experiment was E. coli, due to its lowest reported 
MIC values and its nature as a model organism. Atlantic salmon serum was obtained from 
whole blood left to clot overnight at 4°C, centrifuged at 800 × g for 15 minutes at 4°C to 
remove any residual cells. The assay was carried out as described above with the 
substitution of Atlantic salmon serum for MHB.  
3.2.6 Haemolysis assay 
The haemolytic activities of synthetic peptides P9-4, P11-5, P11-6, and PG-1 were 
assessed as previously described [109, 139]. Briefly, 3 mL of heparinised whole blood was 
collected from visually healthy Atlantic salmon then centrifuged at 1,000 × g for 10 minutes 
at room temperature. The serum and buffy coat were removed and discarded. Red blood 
cells were washed in 10 mL of PBS and centrifuged at 1,000 × g  for 10 minutes. This process 
was repeated three times, discarding the supernatant between washes.  Erythrocytes were 
quantified using a haemocytometer and resuspended to 1x 108 cells/mL in PBS or Atlantic 
salmon serum. Each peptide was serially diluted in sterile water to give final concentrations 
of 800, 400, 200, 100, 50, 25, 12.5 and 6.25 µM. 180 µL of the erythrocyte suspension and 
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20 µL of each concentration of the selected peptides was added to the desired wells of a V-
shaped 96 well microtitre plate.  Control wells contained 20 µL of 2% Triton-X 100 or PBS for 
100% and 0% lysis, respectively. The plates were incubated for 2 hours at room temperature 
then centrifuged at 1,000 × g for 10 minutes. 100 µL of the supernatant from each well was 
transferred to a fresh flat-bottom microtitre plate and the optical density was measured at 
540 nm using a microplate reader. Percentage haemolysis was determined for each 
concentration of peptide by comparison to 100% and 0% lysis using the following formula: 
[(Asynthetic peptide – A0% lysis)/ (A100% lysis – A0% lysis)] x 100, where A is the absorbance at 540 nm. 
3.2.7 Peripheral blood leukocyte (PBL) assay 
The peripheral blood leukocyte (PBL) stimulation was assessed as previously 
described [65]. Briefly, 3 mL heparinised whole blood from visually healthy Atlantic salmon 
was collected and placed on ice. This sample was split into two 2 mL centrifuge tubes and 
progressively spun at 100 × g, 200 × g, and 400 × g for 1 minute, then 800 × g for 2 minutes. 
The buffy coat was harvested from each tube and pooled in fresh 1.5 mL centrifuge tubes, 
resuspended in 1 mL of RPMI, then centrifuged at 400 × g for 5 minutes. The supernatant 
was removed and the final pellet was resuspended in 2 mL of RPMI and split into two 5 mL 
tubes. Cells were quantified with a hemocytometer then diluted with RPMI containing FBS 
(66% FBS/33% RPMI) to a final concentration of 1x1.37 PBLs/mL and 1x 107 RBCs/mL to a 
total volume of 3 mL. Selected peptides (P9-4, P11-5, P11-6) were serially diluted in 1xPBS 
to give final concentrations of 0, 0.5, 5, 50, and 500 µM. Each peptide concentration was 
added to 100 µl of cells to each well of a flat bottom 96 well microtitre plate, in duplicate, 
and incubated at room temperature for 6 hours. No-stimulation controls were included for 
each time point, with 10 µl of PBS instead of peptide. After 6 hours, cells were titrated to 
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resuspend the monolayer and transferred to 1.5 mL centrifuge tubes. Total RNA was 
extracted with 400 µl nucleic acid extraction buffer (4 M urea, 1% SDS, 0.2 M NaCl, 1 mM 
sodium citrate pH 7.5) containing 20 U of proteinase K (Bioline) per sample. After digestion 
protein, cellular debris, and detergent were removed by centrifugation in 7.5 M ammonium 
acetate at 14,000 × g for 5 minute, and nucleic acids were recovered by isopropanol 
precipitation at 16,000 × g for 10 minute followed by an ethanol wash of the nucleic acid 
pellet. Complete removal of DNA was ensured by treatment with 4 units Baseline-Zero 
DNAse (Epicentre) for 30 minutes at 37 °C before the DNAse was removed and the RNA re-
precipitated in 2.5 M LiCl and washed twice in 70% ethanol. The remaining ethanol was 
removed, pellets were resuspended in 12 µL distilled water with RNA secure, and incubated 
at 55°C for 5 minutes with occasional vortexing. Total RNA was quantified and visualized on 
a 1% agarose gel. First strand cDNA was synthesised from total RNA (10 µL) using BioScript 
reverse transcriptase (Bioline, NSW, Australia) with Oligo (dT)18 priming according to 
manufacturer’s instructions. Quantitative real-time PCR (qPCR) was performed on cDNA 
reverse-transcribed from total RNA. The relative expression of IL-8 was measured by qPCR 
using SYBR Green chemistry using CFX ConnectTM Real-time PCR Detection System (Bio-Rad, 
NSW, Australia). Table 3 lists the primers for IL-8 detection and of the reference gene β-
actin. qPCR reactions consisted of 20 µl volumes using a 2x SensiMixPlus SYBR & Fluorescein 
PCR master mix (Bioline), forward and reverse primers (200 nM of each) and 1 µl of cDNA. 
The amplification program was as follows: 95°C for 2m to activate the DNA polymerase 
followed by 40 cycles of 95°C for 5s, 60°C for 20s. At the end of the cycling protocol melt 
curve analysis was run to ensure amplification specificity. mRNA expression levels were 
normalised using the mean expressions of the reference gene, which maintained stable 
expression [140]. The qPCR data were analysed using R Studio (qPCR package) using 
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methods described previously [141, 142]. Data were graphed using GraphPad Prism 5 
(GraphPad Software, Inc.). 
Table 1. Oligonucleotide primers used in real-time PCR experiments. 
Target mRNA Accession # Forward primer (5’  3’) Reverse primer (5’  3’) 
β-actin AF012125 TTGCGGTATCCACGAGAC TAGAGGGAGCCAGAGAGG 
IL-8 BT046706 ACCAGCGAGATAACAA CCAGGAGCACAATGACAA 
 
3.3 Results 
3.3.1 Antibacterial properties of synthetic peptides 
All of the synthetic peptides exhibited low MIC values (100 µM or lower) in the absence of 
salt (Table 4). When the antimicrobial activities were estimated under saline conditions, P9-
4 and PG-1 showed a notable increase in stability towards salts against A. hydrophila and Y. 
ruckeri with MICs of 40µM and 5-20µM respectively. All peptides showed little or no 
antimicrobial capacity in the presence of Atlantic salmon serum (Figure 8). 
 
Table 4. Antibacterial activity of synthetic peptides (µM) in the absence/presence of NaCl. 
Peptide 0 mM 300 mM 0 mM 300 mM 0 mM 300 mM 0 mM 300 mM 
Pathogen A. hydrophila A. hydrophila E. coli  E. coli P. aeruginosa P. aeruginosa Y. ruckeri Y. ruckeri 
P9-4 10 40 2.5 5 5 40 10 40 
P11-5 10 >80 2.5 40 10 >80 20 >80 
P11-6 10 >80 2.5 20 5 >80 5 >80 
HHC10 20 >80 2.5 5 10 >80 10 >80 
K6L2W3 10 >80 2.5 20 10 >80 10 >80 
K7LW3 80 >80 2.5 40 40 >80 2.5 40 
PG-1 40 20 2.5 2.5 5 >80 5 5 
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Pep-1-K 40-80 >80 5 80 20 >80 5 40-80 
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Figure 8. Antimicrobial activity of the peptides P9-4, P11-5, P11-6, and PG-1 against E.coli in 
the presence of Atlantic salmon serum. Data shown are the means ±SD of duplicate wells. 
 
3.3.2 Haemolytic activity of synthetic peptides 
 The synthetic peptides P9-4, P11-5, P11-6, and PG-1 were chosen as candidates for 
cytotoxicity testing due to their relatively low MIC values in previous experiments. To better 
understand how these peptides may interact with eukaryotic cells, we determined their 
ability to lyse Atlantic salmon erythrocytes in both RPMI and heat treated Atlantic salmon 
serum. All peptides were haemolytic to Atlantic salmon erythrocytes (Figure 9). P9-4 caused 
haemolysis of Atlantic salmon erythrocytes at concentrations as low as 2.5 µM, where 
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haemolysis was 19.3%, and up to 42% haemolysis at higher concentrations. The lower 
cytotoxicity exhibited by P11-5 and P11-6 agreed with the previously reported values in 
human red blood cells [102], showing 22.7% and 20.2% haemolysis at concentrations as high 
as 80 µM. PG-1 shows haemolysis as high as 40.2% at 80 µM. In contrast the haemolytic 
activity of all peptides was absent in the presence of Atlantic salmon serum at all 
concentrations (data not shown) after 48h.  
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Figure 9. Haemolytic activity of the peptides P9-4, P11-5, P11-6, and PG-1 to Atlantic salmon 
erythrocytes in RPMI. Data shown are the means ±SD of duplicate wells. 
 
3.3.3 Host immunomodulatory activities of synthetic peptides 
To investigate the possible influence of synthetic peptides on the interleukin-8 production, 
we stimulated a combination of PBLs and RBCs (1.3 x 107 PBLs/mL and 1 x 107 RBC/mL 
respectively) for 6 h with an array of concentrations of P9-4, P11-5, and P11-6 in 
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conventional media (RPMI) and in FBS supplemented RPMI. IL-8 expression was significantly 
upregulated at 6 h post-stimulation at 500 µM with P9-4 and P11-5 in serum. P9-4 induced a 
4 fold increase in IL-8 expression and P11-5 showed a 15 fold increase in IL-8 expression at 
the same concentration (Figure 10). P11-6 showed no biologically significant increase (2 fold 
or greater) in IL-8 expression in either RPMI or FBS with RPMI. All peptides tested showed 
no significant effect on IL-8 in conventional media. 
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Figure 10. IL-8 gene expression in Atlantic salmon peripheral blood leukocytes stimulated 
with P9-4, P11-5, and P11-6. Gene expression was assessed by real-time PCR at 6 h post 
incubation with P9-4, P11-5, and P11-6 at 0.5 µM, 5 µM and 50 µM in RPMI media(A) and 
0.5 µM, 5 µM and 50 µM in 66% FBS supplemented with 33% RPMI(B). Expression was 
normalised to the mean expression of β-actin reference gene. Data shown are the means ± 
SE of quadruplicate PBL samples assayed in duplicate by quantitative real-time PCR and 
presented as fold induction compared to unstimulated control (PBS). * indicates a significant 
fold induction (P<0.05) compared to unstimulated control while the dotted line represents 
the minimum fold change (2 fold) deemed biologically significant. 
 
3.4 Discussion 
 
In the present study, the antimicrobial activity of short synthetic cationic peptides P9-4, 
P11-5, P11-6, and PG-1 were effective in inhibiting two common pathogens of Atlantic 
salmon, A. hydrophila and Y. ruckeri at relatively low concentrations [34, 102, 105, 106, 
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143]. It was previously shown that each of these peptides possesses potent antibacterial 
activity in vitro against mammalian bacterial and fungal pathogens and improved stability in 
the presence of salts [102, 105]. Additionally, the results of this study are in general 
agreement with the antimicrobial activity of these peptides and the previously reported MIC 
values for the representative pathogens E.coli and P. aeruginosa. In comparison, the 
naturally derived Atlantic salmon cathelicidins (asCATH1 and asCATH2) showed no 
antibacterial activity to the same strain of Y. ruckeri up to 80 µM [65]. Furthermore, these 
peptides retain their potent antimicrobial activity when subjected to saline conditions. This 
is notable because many AMPs, including other synthetic analogs, lose their potent 
antimicrobial activity when subjected to physiological salt conditions and are antagonized by 
mono or divalent cations [48]. Additionally, peptides which exert antimicrobial activity in 
artificial media have been shown to lose this activity or function differently within blood or 
serum [36, 61, 144]. Peptide inactivation or degradation may be due to proteolytic 
degradation or other inherent factors present in serum [44, 61]. While peptides exhibited 
low MICs against E. coli in serum-free media, their potent antimicrobial activity was 
diminished in the presence of serum. While PG-1 has been shown to overcome this 
inhibitory effect at concentrations of PG-1 at 100 µg/mL [145], the findings of this work 
suggest that direct application of these peptides at epithelial surfaces may show the highest 
efficacy against bacterial pathogens. 
Low toxicity to host cells is an important trait of any potential therapeutic agent. It has 
been shown that the cell specificity of AMPs is influenced by the net positive charge and 
hydrophobicity of peptides and a balance between the two was necessary to retain potent 
AMPs and avoid hemolytic activity [47]. While some of the peptides in this study caused 
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haemolysis of salmon erythrocytes in PBS, this activity was greatly diminished in the 
presence of serum.  Importantly, the haemolytic activity of all peptides was absent in the 
presence of Atlantic salmon serum at all concentrations after 48 hours (data not shown). 
This suggests that haemolytic activity is unlikely to occur in vivo and that potential host cell 
degradation commonly associated with these peptides would be theoretically limited. 
Despite showing diminished antimicrobial activity in the presence of serum, IL-8 
expression was significantly upregulated at 6 hours post-stimulation at 500 µM for P9-4 and 
P11-5 in conventional media supplemented with FBS.  IL-8 expression has been previously 
reported to be regulated by naturally occurring AMPs (cathelicidins) in humans and Atlantic 
salmon.  IL-8, one of the first CXC chemokines to be discovered in fish, is secreted by 
immune related cells upon interaction with a pathogen and is suggested to attract 
lymphocytes and monocytes to the source of infection whereas IL-8 in mammals usually 
attracts neutrophils [34]. To my knowledge, this is the first study to show induction of 
cytokine expression using short synthetic peptides in fish. In mammalian studies, IDR-1, a 
synthetic HDP, was also shown to enhance the levels of infection-clearing chemokines. 
While not directly antimicrobial in vitro, IDR-1 activated several signaling pathways, 
enhancing expression levels of chemokines and suppressing the levels of pro-inflammatory 
cytokines such as tumor necrosis factor (TNF)-α [146].  
Similarly, previous work using human alpha-Defensin-1 (HNP1), another well-known 
HDP, demonstrated the ability of AMPs to influence immune-related genes and modulate 
the expression of genes encoding proinflammatory cytokines, chemokines, and IFN-
stimulated genes in rainbow trout [111]. Similarly, defensins used as adjuvants in mice 
conferred resistance and acted as chemoattractants for resting human T cells both in vivo 
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and in vitro [147].  In mammals, chemokines have been widely used as adjuvants in vaccines 
against viral infections attracting immune-related cells to the site of inflammation and 
regulating the immune functions of the recruited cells [148]. Modulation of pathogen 
responsive genes and protein expressions may reduce the severity or enable the complete 
protection against pathogen infections. A better understanding of IL-8 expression in 
response to synthetic peptides might enable their use to regulate inflammatory cytokines 
and control localized inflammation during vaccination. While these data look promising, 
further examination of other inflammatory cytokines and immune related genes is 
necessary to better understand possible interactions within the host environment during 
stimulation with non-native peptides.  
In summary, this study demonstrated the modulatory capabilities of two short synthetic 
cationic peptides (P9-4 and P11-5) in their ability to influence expression of the chemokine 
interleukin-8. Interestingly, the potent antimicrobial activity of P9-4, P11-5, P11-6, and PG-1 
against E. coli is negligible in the presence of host serum. Furthermore, this study showed 
that while these peptides have some host haemolytic activity in conventional media, no 
haemolytic activity occurs in the presence of heat inactivated Atlantic salmon serum.  The 
above considerations emphasize the validity and importance of assays which evaluate the 
antimicrobial activities of peptides under conditions potentially relevant to their 
development to function as therapeutic agents in vivo. Additionally, this study further 
demonstrated the efficacy of synthetic peptides as broad spectrum and immunomodulatory 
therapeutic agents with potentially useful aquaculture applications.  
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Chapter 4: Short synthetic cationic peptides increase 
phagocytosis, cell proliferation and respiratory burst in 
Atlantic salmon (Salmo salar L.) head kidney leukocytes
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4.1 Introduction  
 While the majority of past research focused on the direct antimicrobial aspects of 
AMPs, recent research has targeted the immunomodulatory role of bioactive peptides 
during an innate immune response. In particular, defensins and cathelicidins have 
demonstrated their ability to not only induce a proinflammatory immune response in a wide 
variety of immune cells via the production of cytokines but also to suppress the release of 
proinflammatory mediators  induced by LPS and other bacterial products. Additionally, they 
have been shown to promote cell proliferation and phagocytosis by immune-competent 
cells and assist in their ability to differentiate between host and foreign nucleic acids [52, 
57-59, 64].  Because of the multifaceted mechanisms of these molecules, it has been 
suggested that peptides which exhibit primarily antimicrobial activity be referred to as 
AMPs whereas the term host defense peptides (HPDs) should be used for those peptides 
with immunomodulatory abilities [95].   
Although these natural peptides exhibit potential as anti-infective agents, the 
commercial application of these peptides has been limited for a variety of reasons. While 
many AMPs have been shown to inhibit the growth of bacteria at relatively low minimum 
inhibitory concentrations (MIC) in vitro, they fail to confer the same level of protection in 
vivo [24, 94].  Moreover, their amino acid composition and non-selective nature has shown 
them to be haemolytic to host cells at higher concentrations, and are susceptible to 
inactivation via salts at physiological concentrations and other components found naturally 
in blood and serum [36, 44, 45, 65]. Arguably, the single largest issue related to natural 
peptide production is the high cost associated with their synthesis. Peptides are commonly 
produced through solid-phase chemical synthesis and to a lesser extent recombinant DNA 
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methods using biological production systems [24, 95, 96]. Further, many require post-
transcriptional modification to produce functional mature peptides [96].  In short, the purity 
and scale of production limit the use of naturally occurring AMPs as therapeutics.      
The development of non-natural or synthetic AMPs is emerging as an effective 
strategy to circumvent many of the issues associated with naturally-produced AMPs. The 
design and production of synthetically derived peptides has been extensively reviewed in 
the literature [43, 95, 103, 104, 106].  These peptides can be optimized through amino acid 
substitution to produce small, cost effective peptides with increased antimicrobial activity 
[149, 150] and target specificity [103, 145], low cytotoxicity [102], notable salt tolerances 
[143, 149, 151], improved bioavailability [44, 151], and immunomodulatory capabilities 
[152-154]. While the use of synthetic peptides has been documented in mammalian models, 
there are currently no studies which test the capabilities of these peptides in teleost fish. 
The aim of this study was to assess the ability of a range of small synthetic cationic 
peptides to modulate the immune functions of head kidney leukocytes in Atlantic salmon 
(Salmo salar). Functional assays to assess the direct stimulatory capacity of these peptides 
on immune competent cells were undertaken to explore their potential use as 
immunostimulatory compounds in fish. 
4.2  Materials and Methods 
4.2.1 Ethics statement 
All work involving animals was approved by the University of Tasmania Animal Ethics 
Committee in accordance with the Australian Code of Practice for the Care and Use of 
Animals for Scientific Purposes.  
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4.2.2 Peptides, Peptide Synthesis, and Reagents 
Peptides were synthesized by Life Research Australia (VIC, Australia) using solid-phase 
standard 9-fluorenyl methoxy carbonyl chemistry and purified to >95% by reverse-phase 
high-pressure liquid chromatography (Table 5). Mass spectral analysis and HPLC 
chromatography were used to ensure purity and the identity of each peptide. 
Oligodeoxynucleotide 1668 (TCCATGACGTTCCTGATGCT), phosphorothioated to 
increase resistance to nuclease degradation, was purchased from Sigma Genosys (Castle Hill, 
NSW, Australia). It was selected as a positive control based on its proven stimulatory 
abilities in Atlantic salmon, rainbow trout, other teleost fish, and murine studies [118-121]. 
 
Table 5. List of synthetic AMPs used in this study. 
 
Peptide Sequence Molecular 
weight 
(g/mol) 
Purity (%) Notes Ref. 
P9-4 Ac-KWRRWIRWL- 
NH2 
1440.78 95.50 improved stability in the presence of 
salts 
 
low cytotoxicity compared to reference 
peptide 
 
[102] 
P11-5 Ac-GKLFKKILKIL- 
NH2 
1341.80 96.89 [102] 
P11-6 Ac-KKLIKKILKIL- NH2 1378.91 96.97 [102] 
HHC10 Ac-KRWWKWIRW- 
NH2 
1485.82 99.27 protects mice against invasive S. aureus 
infections through intravenous (IV) 
injection 
[106] 
K6L2W3 Ac-KLWKKWKKWLK-
NH2 
1613.09 96.84 suppressed LPS-induced inducible nitric 
oxide synthase (iNOS) mRNA expression 
and inhibited release of nitric oxide (NO) 
following LPS stimulation in RAW264.7 
cells 
[103] 
PG-1 Ac-
RGGRLCYCRRRFCVC
VGR-NH2 
2201.68 96.54 synergistically enhanced respiratory 
burst when coupled with endotoxin in 
human monocytic cell lines 
[50]  
 
51 | P a g e  
   
P a g e  | 52 
 
4.2.3 Fish 
Atlantic salmon weighing approximately 200-300 g were maintained in a 3000 L 
freshwater water re-circulating tank with biofilter at IMAS Launceston, University of 
Tasmania, Launceston, Australia.  
4.2.4 Isolation of head kidney leukocytes  
Head kidney leukocytes were isolated as previously described [122]. Briefly, head 
kidney was aseptically removed from each fish and passed through a 100 µM sterilized 
metal mesh repeatedly using L-15 medium containing 1% penicillin and streptomycin (P/S) 
(Sigma), 0.2% heparin (20 U/mL) (Sigma). Cell suspensions were then placed on a 34/54% 
Percoll (Sigma) gradient and centrifuged at 400 g for 40 minutes at 4°C. After centrifugation, 
cells were harvested from the 34/54% interface and washed twice in phosphate buffered 
solution (PBS, Sigma). Cells were quantified by trypan blue exclusion using a 
haemocytometer and resuspended in the L-15 media mentioned above for use in their 
respective assays. 
4.2.5 Phagocytosis assay 
Phagocytosis was assessed using a modified previously described method [123]. 
Briefly, cells were seeded in 96-well plates at a density of 1 x 107 cells per well, and allowed 
to adhere at 18°C for 3 hour. Wells were then washed three times with L-15 medium 
containing 1% penicillin and streptomycin to remove any non-adherent cells. Cells were 
stimulated with a synthetic peptide (5 µM) or CpG-ODN 1668 (5 µM) for 4 hour at 18°C. 
Control leukocytes were incubated with L-15 medium alone. After the incubation period, 20 
µL Congo red-stained yeast cells (107 cells/mL) were added to each well. To monitor 
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phagocytosis, two pictures were taken randomly by a Cannon 600D Digital SLR with an 
optical adapter equipped to a light microscope at given time points. The phagocytic activity 
(PA) was determined by the percentage of cells with engulfed yeast cells (PA = number of 
phagocytic cells with engulfed bacteria/number of phagocytes). The phagocytic index (PI) 
was determined by the number of engulfed yeast cells per cell (PI = number of engulfed 
yeast/phagocytic cells). 
4.2.6 Respiratory burst activity assay 
Respiratory burst activity was assessed by nitro blue tetrazolium (NBT) (Sigma) 
reduction to formazan after stimulation of cells as previously described [123]. Briefly, cells 
were isolated and 96-well plates were prepared and stimulated for 4 hours at 18°C as stated 
above. Untreated leukocytes were used as the negative control and leukocytes treated with 
phorbol myristate acetate (PMA) (100 ng/mL) as the positive control. After stimulation, the 
cell monolayer was washed twice with PBS to remove any residual stimulant and 100 µL of 
NBT solution (1 mg/mL in L-15) was added per well. Cultures were then incubated at 18°C 
for 1 hour. After incubation, cells were fixed with methanol after the removal of the NBT 
solution. Cells were then air dried for 20 minutes then washed again to remove residual 
methanol. Finally, 120 µL 2M KOH and 140 µL of DMSO (Sigma) were added to each well 
and the optical density was measured with an Infinite M200 Pro microplate reader (Tecan) 
at 620 nm.  
4.2.7 Cell proliferation assay 
 Cell proliferation was assessed by measuring total nucleic acid content of lysed cells 
after stimulation treatments using a fluorometer. Briefly, cells were seeded in 96-well plates 
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at a density of 1 x 105 cells per well, and allowed to adhere at 18°C for 3 hours. Wells were 
then washed three times with L-15 medium containing 1% penicillin and streptomycin and 
to remove any non-adherent cells. Cells were stimulated with a synthetic peptide (5 µM) or 
CpG-ODN 1668 (5 µM) for 5 days at 18°C. Control leukocytes were incubated with L-15 
medium alone. Cells were immediately frozen after stimulation. Total nucleic acid was 
extracted as previously described with modification [124]. Briefly, previously stimulated 96-
well plates were thawed and 300 µL nucleic acid extraction buffer (4M urea, 1% SDS, 0.2 M 
NaCl, 1 mM sodium citrate pH 7.5) containing 20 U of proteinase K (Bioline) per sample was 
added to each well. 96-well plates were then placed on ice and allowed to digest for 30 
minutes. Samples were transferred from their wells into 1.5 mL microcentrifuge tubes. 
Protein, cellular debris, and detergent were removed by centrifugation in 7.5M ammonium 
acetate at 14,000 x g for 5 minutes, and nucleic acids were recovered by isopropanol 
precipitation at 16,000 x g for 10 min followed by an ethanol wash of the nucleic acid pellet. 
Complete removal of RNA was ensured by treatment with 4 units RNase A (Sigma) for 30 
min at 37°C. Samples were then resuspended in molecular water and quantified using a 
Qubit fluorometer (Invitrogen) using the manufacturer’s protocol. 
4.2.8 Statistical analysis 
Statistical analysis was carried out using GRAPHPADTM PRISM version 5.00 for 
WINDOWS® (GraphPad Software). Differences between groups were determined using a 
one-way ANOVA with a Tukey posthoc test. Data were subject to a Shapiro–Wilk's test for normality 
and a Levene's test for equality of variances to satisfy the assumptions required for an ANOVA. 
Results were considered significant if P < 0.05. 
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 4.3 Results 
4.3.1 Phagocytosis assay 
Phagocytic activity of head kidney leukocytes stimulated with various synthetic cationic peptides 
(5 µM), CpG-ODN 1668 (5 µM) or an untreated cell control differed significantly between treatments 
(F [7, 16] = 18.79, P < 0.0001; Figure 11A). A Tukey’s post-hoc analysis of the groups indicated that 
there was a significant increase in the phagocytic activity of the groups stimulated with K6L2W3 and 
HHC-10 compared to the untreated control group and all other peptides tested (P < 0.05). In 
addition CpG-ODN 1668 had a significantly higher phagocytic activity than all other treatments (P < 
0.05). Moreover, differences in phagocytic index existed between treatments (F [3, 8] = 0.6703, P 
=0.5938; Figure 11B) with the groups stimulated with K6L2W3 and HHC-10 showing significantly 
improved phagocytic index in comparison to the untreated group as well as PG-1, P11-5, and CpG-
ODN 1668. 
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Figure 11. Phagocytic activity (A) and phagocytic index (B) of Atlantic salmon (S. salar)  head 
kidney leukocytes stimulated with individual synthetic AMPs (5 µM), or CpG-ODN 1668 (5 
µM). The phagocytic activity (PA) was determined as the percentage of cells with engulfed 
yeast cells. The phagocytic index (PI) was determined as the number of engulfed yeast cells 
per cell. Control leukocytes were incubated with medium alone. Data shown are the means 
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± SE of quadruplicate HKL samples assayed from 3 fish. Different superscript letters indicate 
significant differences between the groups (P <0.05). 
4.3.2 Respiratory burst assay 
Respiratory burst activity of head kidney leukocytes stimulated with stimulated with 
various synthetic cationic peptides (5 µM), CpG-ODN 1668 (5 µM), PMA (100 ng/mL), or an 
untreated cell control differed significantly between treatments (F [7, 16] = 56.07, P < 0.0001; 
Figure 12). A Tukey’s post-hoc analysis indicated that there was a significant increase in the 
NBT reduction by the groups stimulated with PG-1, P11-6, K6L2W3, and HHC-10 compared to 
the control but not to the groups stimulated by P9-4 and P11-5 (P < 0.05). The positive 
control, PMA, was significantly different than all other treatments (P < 0.05). There was no 
significant difference between P9-4, P11-5, and the untreated control.  
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Figure 12. Respiratory burst activity of Atlantic salmon (S. salar) head kidney leukocytes 
stimulated with individual synthetic AMPs (5 µM), or CpG-ODN 1668 (5 µM). Control 
leukocytes were incubated with medium alone and positive controls were treated with PMA 
(100 ng/ml). Data shown are the means ± SE of quadruplicate HKL samples assayed from 3 
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fish at 620 nm after 60 minutes incubation. Different superscript letters indicate significant 
differences between the groups (P <0.05). 
4.3.3 Cell proliferation assay 
Proliferation of head kidney leukocytes stimulated with various synthetic cationic 
peptides (5 µM), CpG-ODN 1668 (5 µM), or an untreated cell control differed significantly 
between treatments (F [7, 16] = 36.99, P < 0.0001; Figure 13). A Tukey’s post-hoc analysis of 
the groups indicated that there was a significant increase in total DNA yield from cells 
treated with HHC-10 compared to the peptides P9-4, P11-6, and the untreated control but 
not PG-1, P11-5, and K6L2W3 (P < 0.05). Cells stimulated with CpG-ODN 1668 had a 
significantly higher total DNA yield than all other treatments (P < 0.05). 
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Figure 13. Cell proliferation of Atlantic salmon (S. salar) head kidney leukocytes stimulated 
with individual synthetic AMPs (5 µM), or CpG-ODN 1668 (5 µM) for 5 days. Control 
leukocytes were incubated with medium alone. Data shown are the means ± SE of 
quadruplicate HKL samples assayed from 3 fish. Different superscript letters indicate 
significant differences between the groups (P <0.05). 
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4.4 Discussion  
Phagocytic cells play an integral role in the destruction, clearance, and mediation of 
bacterial pathogens. During an infection, phagocytes are triggered by cytokines or bacterial 
components to migrate to inflammatory sites. Once there, phagocytes attach to foreign 
particles and ingest them. Intracellular destruction of pathogens is achieved by a variety of 
bactericidal mechanisms including the production of AMPs, degradative enzymes, oxygen 
intermediates, or nitrogen intermediates [10, 155].  
In the current study, the ability of novel synthetic cationic peptides to stimulate the 
phagocytic process of Atlantic salmon head kidney leukocytes in vitro was demonstrated for 
the first time. Peptides K6L2W3 and HHC-10 significantly increased phagocytic activity of 
adherent head kidney leukocytes as compared to the other peptide treatments and the 
untreated controls. Additionally, cells stimulated with these peptides ingested more yeast 
per phagocytic cell with some variability between peptide treatments. HHC-10 increased cell 
proliferation in leukocytes stimulated for 5 days. Moreover four of the six peptides tested 
were capable of significantly influencing respiratory burst activity. The production of 
superoxide anion and the conversion of this into a large variety of reactive oxygen species 
(ROS)  by phagocytes is a result of the activation of  the NADPH oxidase complex and is 
generally associated with immune stimulation [10, 37]. This may represent a non-specific 
response by these cells to foreign peptides, as some but not all of these peptides elicited a 
response in other phagocytic functions.  
 Due to the novel nature of these peptides and their recent emergence, only a 
handful of scientific papers discussed the use of these specific peptides with most of their 
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putative functions closely associated to mammalian biology and drug development [102, 
103, 156]. Many of the methods used in mammalian studies lie well beyond the scope of 
current fish immunological studies.  Nonetheless, some interesting findings and implications 
relevant to teleosts are still apparent. HHC-10, a de novo designed peptide, demonstrated 
significant in vitro inhibitory activity against antibiotic-resistant “Superbug” bacteria (i.e. 
strains of exceptionally resilient bacteria) in preliminary work and in many cases  
outpreformed many of the most potent conventional antibiotics commonly used to treat 
these bacteria [106]. Furthermore, HHC-10 demonstrated substantially lower toxicity 
compared to MX-226, a peptide from advanced clinical trials, and conferred significant 
protection when administered to mice through intravenous (IV) injection [106]. In the only 
other available study involving this peptide, HHC-10 was capable of inhibiting the M. 
tuberculosis complex bacteria in vitro and in vivo [156]. Additionally, it was shown that HHC-
10 administration to infected mice resulted in a significant reduction of IFN-γ transcription 
[156]. Previous research involving K6L2W3, an 11-mer cationic Trp-rich peptide modelled 
after Indolicidin, suggested this peptide might have anti-inflammatory activities. While our 
results showed that this peptide significantly induced respiratory burst through the 
production of superoxide anion in salmon leukocytes, K6L2W3 suppressed LPS-induced nitric 
oxide synthase (iNOS) mRNA expression and inhibited release of nitric oxide (NO) following 
LPS stimulation in RAW264.7 cells [103]. Additionally, PG-1 was previously shown to 
neutralize TNF-α or nitric oxide, in a dose-dependent manner, when induced by endotoxin. 
However, macrophages co-treated with combinations of PG-1 and endotoxin  had enhanced 
the respiratory burst and increased ROS  release [50]. These results indicate that priming of 
immune cells by synthetic peptides may result in varying and multifaceted effects on 
immune function including the induction and suppression of both pro- and anti-
59 | P a g e  
   
P a g e  | 60 
 
inflammatory responses according to different cellular responses [97]. Moreover, while our 
method provides a simple and straight forward measurement of superoxide anion, no 
measurement of nitric oxide or other ROS was conducted. Future work should target 
specific cellular receptors which may indicate the induction pathway stimulated by these 
peptides in fish. Furthermore, the application of more advanced cell recognition 
technologies such as flow cytometry may provide a better understanding of potential cell 
specific activation of synthetic cationic peptides. This information could lead to the 
development of peptides with more selective, cell specific stimulation and therefore a more 
targeted approach for applications such as immunostimulants or adjuvants.  
It is important to note that while only a few researchers used the same specific 
peptides as this study, there is increasing evidence for the immunomodulatory properties of 
synthetic cationic peptides, such as the innate defense regulators (IDRs). Three key 
examples of IDRs which show immunomodulatory properties are IDR-HH2, IDR-1002, and 
IDR-1018. IDR-HH2, IDR-1002, and IDR0-1018 promoted the release of other host defense 
peptides (HDPs) such as human α-defensins, and LL-37 as well as enhanced neutrophil-
triggered killing of E. coli in vitro [157]. Additionally, IDR-1018 induced macrophage 
differentiation exhibited a unique combination of immune responses including production 
of both pro and anti-inflammatory mediators and increased phagocytosis of apoptotic cells 
in human macrophages [158]. Moreover, these peptides suppressed LPS-induced 
proinflammatory cytokine and ROS production in neutrophils whereas the control peptide 
IDR-1035 did not. These findings provide further evidence for peptide specific activation of 
immune cells as well as exhibit the regulatory capabilities of these peptides.  
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 4.5 Conclusion 
In conclusion, the capability of synthetic cationic peptides to improve the immune 
functions of Atlantic salmon leukocytes in vitro was demonstrated. Our results indicate that 
K6L2W3 and HHC-10 significantly enhanced leukocyte phagocytic activity and phagocytic 
index. Additionally, PG-1, P11-6, K6L2W3 and HHC-10 improved respiratory burst through 
increased superoxide anion production while HHC-10 alone increased cell proliferation in in 
vitro tests. While these findings provide preliminary evidence for the use of short, cationic 
synthetic AMPs as inducers of improved phagocytic function in fish, further experimentation 
is required to elucidate the mechanism of their activity and better understand the non-
specific effects associated with these peptides. 
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Chapter 5: General Discussion
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This work demonstrates that novel synthetic peptides and natural (synthesized) cathelicidins 
stimulate the phagocytic process of non-mammalian leukocytes in vitro. This study showed that 
selected synthetic AMPs and asCATH2 were capable of improving Atlantic salmon leukocyte 
phagocytic activity, increasing respiratory burst, and inducing cell proliferation in vitro. Furthermore, 
two synthetic peptides (P9-4 and P11-5) had the capacity to influence expression of the chemokine 
interleukin-8 in peripheral blood leukocytes (PBLs) in vitro. As all of these mechanisms play an 
important role in innate immunity. This work demonstrates the dynamic nature of these peptides to 
act not only as bactericidal agents but also potent effector molecules.  
AsCATH2 was previously shown to increase expression of IL-8 in PBLs at biologically relevant 
concentrations in vitro [65]. The current study shows that this stimulatory ability extends to other 
immune cell lineages as well. Additionally, the functional differences highlighted by in this work 
positively reinforce the idea that asCATH2 primarily serves to modulate cell function whereas 
asCATH1 is directly antibacterial.  While four of the six synthetic peptides tested were capable of 
significantly influencing respiratory burst activity, the notable standout from the functional assays 
was HHC-10 which also significantly improved phagocytic activity and increased cell proliferation 
after 5 days of stimulation. As mentioned previously (Chapter 4), HHC-10 was loosely developed 
based on a naturally occurring bovine peptide called Bac2A and variable amino acid substitution. 
This initial work produced two subsets of peptides, through SPOT synthesis, which contained nearly 
1500 peptides [106]. The developers then utilized the amino acid sequences of these peptides to 
create quantitative structure-activity relationships (QSAR) models which relate biological relevant 
chemical characteristics to antimicrobial activity. Additionally, an artificial neural network was used 
to relate chemical descriptors to antimicrobial activity for the 100, 000 computer generated peptides 
[106]. The result: a peptide with significant in vitro inhibitory activity against a variety of antibiotic-
resistant bacteria and high in vivo efficacy when administered to mice (see Chapter 4). In the current 
study, HHC-10 significantly effected phagocytic cells and induced cell proliferation. In retrospect, this 
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peptide should have been considered for gene expression analysis whereas P9-4, P11-5, P11-6, and 
PG-1 were selected instead. 
While this work demonstrates the ability of AMPs to directly stimulate and modulate 
phagocytic cell function, the mechanism by which this occurs is still unclear. Most likely AMPs act 
through the non-specific activation of PRRs. It is known that PRRs are able to trigger various innate 
immune responses including complement pathways, apoptosis, leukocyte activation and migration, 
and cytokine production [159].These peptides, like  many other soluble immune products, may have 
divergent effects on immune cells that depend on their concentration and the combinatorial effects 
elicited by the array of factors present at a particular site. Reactive oxygen and nitrogen 
intermediates act as potent signaling molecules at low doses and their role as inflammatory 
mediators to promote cell proliferation and differentiation is already evident in teleost fish [160]. 
While the exact mechanism and subsequent activation pathway is unknown in fish, in mammals this 
is largely accomplished through the modulation of expression of survival proteins through 
transcriptional regulators like NF-κB  and activation of signaling kinases that include MAP kinase and 
protein kinase C [161]. These kinases are integral to the regulation of antimicrobial functions that 
include cellular motility, phagocytosis, and cytokine production [161].  
The second major goal of this thesis was to explore the use of short, synthetic cationic 
peptides as novel antibiotics for future aquaculture application (Chapter 3 and 4). Previous work 
involving the salmonid cathelicidins had already established their antibacterial capabilities against 
aquaculturally important bacterial pathogens [65]. Here it is shown that P9-4, P11-5, P11-6, and PG-
1 were effective in inhibiting A. hydrophila, Y. ruckeri, E.coli, and P. aeruginosa at relatively low 
concentrations. Additionally, the antimicrobial activity seen against the latter two pathogens agreed 
with previously published data [34, 102, 105, 106, 143]. Despite the promising previous results, the 
potent antimicrobial activity of P9-4, P11-5, P11-6, and PG-1 was negligible in the presence of host 
serum. However, previous work involving PG-1 showed that this peptide protected mice from a 
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lethal challenge of S. aureus or vancomycin-resistant Enterococcus faecium (VREF) in vivo. In those 
studies, PG-1 was as effective as the conventional antibiotic vancomycin in treating MRSA-induced 
bloodstream infections and could be delivered up to 60 min after infection by intraperitoneal 
injection. It was demonstrated that the peptide did not translocate from the site of injection. This 
indicates  that while the synthetic peptides seemingly underperformed in serum in vitro, they could 
be used for localized applications in vivo.     
Many of the issues associated with peptide inactivation or loss of activity can be overcome 
during synthesis through modification. One method involves the incorporation of unnatural amino 
acids to improve protease stability. The addition of unnatural amino acids to peptide sequences 
greatly reduces or halts the proteolytic degradation process because they are not readily recognized 
by the binding sites of proteases [99]. Among the various unnatural α-amino acids, substitution of 
AMPs with D-amino acids is the most popular approach due to the commercial availability of the D-
form of all 20 naturally occurring amino acids [99]. Additionally, the production of peptoids is 
another way to confer protease stability. Peptoids, or poly-N-substituted glycines, contain side 
chains appended to the nitrogen atom of the peptide backbone instead of the α-carbons in amino 
acids [99, 151, 162].Notably, K6L2W3 a peptide used in this thesis, has had both forms of modification 
done to it with interesting results. K6L2W3-D showed improved resistance to trypsin degradation 
compared to the parent peptide K6L2W3  [103]. Furthermore, it along with K6L2W3 inhibited LPS-
induced nitric oxide synthase (iNOS) mRNA expression and the release of nitric oxide (NO) following 
LPS stimulation by binding to LPS in RAW264.7 cells [103]. The peptoid k6l2w3 improved upon the 
design of its parent peptide by retaining potent antimicrobial activities against E. coli and S. aureus 
after trypsin treatment [162]. Subsequent studies investigating the direct antimicrobial activity of 
the peptides tested in this thesis might opt to redesign or modify the current peptides with either of 
the previously described methods to improve their resistance against degradation and thus 
potentially improve their application for biologically relevant conditions.   Future work on the 
synthetic AMPs in Atlantic salmon could aim to develop signaling inhibitors in order to elucidate 
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cellular targets for peptide activation (both extracellular and intracellular). Additional research could 
explore the potential of aquaculturally-relevant bacteria strains to develop resistance towards these 
synthetic AMPs after multiple generations of subculture and treatment. This work would provide 
valuable information regarding the susceptibility of particularly problematic microbes towards these 
peptides.        
While the likelihood that the AMPs in this work will be used as direct antibacterial agents 
beyond topical applications is low, due to their loss of bactericidal function in serum, these results 
indicate that their immunomodulatory capabilities demonstrate potential as adjuvants for 
vaccination. Adjuvants, substances which enhance host immune response to antigen, are used to 
improve vaccine efficacy by boosting the less-immunogenic potential of vaccines, extending the 
duration of protection, and/or directing the immune response [40, 163].  Administration of vaccines 
can be performed orally through feed incorporation, by immersion in diluted vaccine suspensions, or 
by intraperitoneal or intramuscular injection routes [164]. Oil emulsions such as Freund’s complete 
or incomplete adjuvant (FCA/FIA) which contain mineral oil and a surfactant are commonly used in 
experimental injection vaccinations to generate long-term immune responses with various antigens 
[163, 164]. While cost effective, these adjuvants have been associated with a variety of severe side 
effects including injection site granuloma and localized toxicity in some species [165-167].  
AMPs have been shown to both induce and inhibit a wide variety of inflammatory responses 
[147, 148]. While this work presents no direct evidence for the in vivo efficacy of the selected 
peptides used in this study, AMPs have already been targeted as potential novel adjuvant which 
could modulate the inflammation associated with vaccination and therefore limit localized damage 
commonly associated with conventional adjuvants [163].    A recent study showed that tilapia alpha-
helical AMPs Oreochromicins are able to boost immune response in mammals and fish when co-
administered with ovalbumin in mice and my32-Ls, a sea lice (Lepeophtheirus salmonis) antigen in 
fish [168]. Another study in zebrafish (Danio rerio) demonstrated that zfBD2 (zebrafish beta-defensin 
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2) possessed diverse immunomodulatory activity both in vitro and in vivo [92]. This beta-defensin in 
combination with a DNA vaccine conferred protection levels > 90% against a lethal spring viraemia of 
carp virus (SVCV) challenge. Moreover, while this DNA vaccine was previously shown to partially 
protect fish (50-80%) [169], co-administration with zfDB2 lowered the required dose of the vaccine 
from 10µg to 1µg and improved protection against SVCV [92]. Additionally, AMPs can be formulated 
with other immunogenic compounds/delivery methods to further improve their efficacy. Pleurocidin 
(PLE) and an outer membrane protein, glyceraldehyde-3-phosphate dehydrogenase produced 
recombinantly in V. harveyi (rGAPDH)   were simultaneously encapsulated into microparticles using a 
biodegradable polymer and used to immunize grouper (Epinephelus coioides) against V. harveyi. 
Microparticles containing PLE conferred a significantly higher survival rate (85%) than that induced 
by microparticles containing rGAPDH alone (67%) [170]. In mammals, synthetic cell penetrating 
AMPs are being used as cationic delivery systems for immunogenic compounds including CpG-ODNs 
[171, 172] and TLR-agonists [173] with promising results.  
With the rapid increase of technology, particularly in the areas of computer-aided peptide 
design, it is inevitable that many new potential peptides will emerge with improved functionality and 
cell specificity. Therefore, this thesis provides groundwork for those interested in this field with an 
emphasis on the functional applications of these peptides in vitro.  
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